A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
1. To evaluate the safety and tolerability of xy0206 as single drug in the treatment of relapsed / refractory AML;
2. Evaluate the dose limited toxicity (DLT) and maximum tolerable dose (MTD) of xy0206 as single drug in the treatment of relapsed / refractory AML subjects.
3. To evaluate the pharmacokinetic (PK), pharmacokinetic (PD) characteristics and PK / PD correlation of xy0206 as single drug treatment in relapsed / refractory AML subjects;
4. To evaluate the primary efficacy of xy0206 as single drug in the treatment of relapsed / refractory AML patients;
5. To evaluate biomarkers of xy0206 as single drug treatment for relapsed / refractory AML subjects.
Acute Myeloid Leukemia
DRUG: XY0206
Maximum tolerable dose, The occurrence of Maximum tolerable dose., from the start of the medication to the end of the study or 28 days after cessation of medication|Dose limiting toxicity, The occurrence of Dose limiting toxicity., from the start of the medication to the end of the study or 28 days after cessation of medication|Adverse event, The occurrence rate of Adverse event., from the start of the medication to the end of the study or 28 days after cessation of medication|Adverse drug reactions, The occurrence rate of adverse drug reactions., from the start of the medication to the end of the study or 28 days after cessation of medication|Serious adverse events, The occurrence rate of Serious adverse events., from the start of the medication to the end of the study or 28 days after cessation of medication|Blood routine, Check whether the red blood cell system, white blood cell system and platelet system are normal, from the start of the medication to the end of the study or 28 days after cessation of medication|Urine routine, Urine routine examination includes urine color, transparency, pH, red blood cells, white blood cells, epithelial cells, tube type, protein, specific gravity and urine sugar., from the start of the medication to the end of the study or 28 days after cessation of medication|Stool routine, Routine stool tests include the detection of red and white blood cells in feces, bacterial sensitivity test, occult blood test (OB) and inspection of eggs., from the start of the medication to the end of the study or 28 days after cessation of medication|Blood biochemistry, The contents of various ions, sugars, lipids, proteins, enzymes, hormones and metabolites in blood were detected, from the start of the medication to the end of the study or 28 days after cessation of medication|Serum amylase / lipase, Evaluation of pancreatic function, from the start of the medication to the end of the study or 28 days after cessation of medication|Coagulation function, Four coagulation parameters including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen (FIB) were evaluated., from the start of the medication to the end of the study or 28 days after cessation of medication|ECG, Evaluation of QT interval, from the start of the medication to the end of the study or 28 days after cessation of medication|Echocardiography, To evaluate the electrophysiological condition of the heart, from the start of the medication to the end of the study or 28 days after cessation of medication|Imaging examination, Chest X-ray/CT, from the start of the medication to the end of the study or 28 days after cessation of medication|Body temperature, One of the vital signs., from the start of the medication to the end of the study or 28 days after cessation of medication|Blood pressure, Assess whether systolic blood pressure and diastolic blood pressure are normal, from the start of the medication to the end of the study or 28 days after cessation of medication|Heart rate, One of the vital signs., from the start of the medication to the end of the study or 28 days after cessation of medication|Breathing, Assess if breathing is normal, from the start of the medication to the end of the study or 28 days after cessation of medication|Skin, Assess if the skin is normal., from the start of the medication to the end of the study or 28 days after cessation of medication|Head, Head examination includes head, eyes, ears, nose, lips, etc.Assess if head is normal, from the start of the medication to the end of the study or 28 days after cessation of medication|Neck, Neck examination includes thyroid gland, lymph node, etc.Assess if neck is normal., from the start of the medication to the end of the study or 28 days after cessation of medication|Chest, Chest examination includes lung, cardiovascular, etc.Assess if chest is normal., from the start of the medication to the end of the study or 28 days after cessation of medication|Abdomen, Abdominal examination includes liver and spleen.Assess if abdomen is normal., from the start of the medication to the end of the study or 28 days after cessation of medication|Limbs, Assess if limbs is normal., from the start of the medication to the end of the study or 28 days after cessation of medication|Nerves, Assess nerve function by communication, from the start of the medication to the end of the study or 28 days after cessation of medication|Back/spine, Assess if back/spine is normal., from the start of the medication to the end of the study or 28 days after cessation of medication
1. To evaluate the safety and tolerability of xy0206 as single drug in the treatment of relapsed / refractory AML;
2. Evaluate the dose limited toxicity (DLT) and maximum tolerable dose (MTD) of xy0206 as single drug in the treatment of relapsed / refractory AML subjects.
3. To evaluate the pharmacokinetic (PK), pharmacokinetic (PD) characteristics and PK / PD correlation of xy0206 as single drug treatment in relapsed / refractory AML subjects;
4. To evaluate the primary efficacy of xy0206 as single drug in the treatment of relapsed / refractory AML patients;
5. To evaluate biomarkers of xy0206 as single drug treatment for relapsed / refractory AML subjects.